Lazăr Daniela, Tăban Sorina, Dema Alis, Cornianu Mărioara, Goldiş A, Raţiu Iulia, Sporea I
Department of Gastroenterology, "Victor Babeş" University of Medicine and Pharmacy, Timisoara, Romania.
Rom J Morphol Embryol. 2009;50(1):41-50.
The prognosis of the gastric cancer is generally reserved. The purpose of this study consists in the identification of the clinicopathological parameters that influence the prognosis of the patients that underwent surgery for gastric cancer.
Out of a total amount of 265 patients (186 males and 79 females) clinically and histopathologically diagnosed with gastric cancer, 61 patients operated for this disease have been selected from the Surgical Departments of the Emergency County Hospital in Timisoara. A prospective study was conducted on this group, regarding the gastric cancer's evolution and aggressiveness, for a period of 5 years. The survival time was calculated starting with the month when the surgery took place, and up to the month of death or that of the survival confirmation, and the survival rate was represented by the percentage of survivals at the end of the tracked period (in years and months).
The study group was formed of 61 patients (43 males and 18 females) of ages between 30 and 80 years (mean age = 59.34 years). Gastric cancer was encountered more frequently in males (70.5%) than in females (29.5%) (p<0.001 ES). The amount of gastric cancer cases grows with age, the highest percent being observed in patients from the 51-70 years age group. However, the incidence is significantly lower after the age of 71 - 8.2% (p<0.001 ES). Antral localization of the gastric cancer predominates in both males and females, for all the age groups (50.8%). The average 5 years survival rate, for the whole group has been of 16.4%. We remark the extremely low survival rate for the older patients. In our study, we have identified five early gastric carcinomas (8.2%), classified as being type I protrusive tumors of intestinal type and 56 advanced gastric carcinomas, 16 cases in females (28.6%) and 40 cases in males (71.4%). The average survival for the patients with advanced gastric cancers was of 13.9 months, significantly lower than the average survival value of the patients with early gastric cancers (57.2 months). According to Borrmann's classification, we have identified five type I carcinomas (8.9%), 20 type II carcinomas (35.7%), 22 type III carcinomas (39.3%), and nine type IV carcinomas (16.1%). We did not notice any significant differences between the survival values of the patients with tumors of types I, II and III (p>0.05 NS), but the patients with diffuse infiltrative gastric cancers had an average survival of only 4.9 months after the surgery.
The prognosis for gastric cancer is reserved, the 5 years average survival rate is of 16.4%. We have noticed a significantly decrease of survival rate with age (p = 0.024688 S). The 5 years survival is of 10.7% for patients with advanced cancers, significantly lower than the 5 years survival of 80% for patients with early gastric cancers (p<0.001 ES).The ulcerative-infiltrative type of cancer is predominant (39.3%). The patients with diffuse infiltrative forms of gastric cancers survived for an average period of only 4.9 months after surgical intervention.
胃癌的预后通常不容乐观。本研究旨在确定影响接受胃癌手术患者预后的临床病理参数。
从蒂米什瓦拉县急救医院外科选出61例因胃癌接受手术的患者,这些患者共计265例(186例男性和79例女性),均经过临床和组织病理学诊断为胃癌。对该组患者进行了一项为期5年的前瞻性研究,观察胃癌的进展和侵袭性。生存时间从手术当月开始计算,直至死亡或生存确认的月份,生存率以追踪期(年和月)结束时存活者的百分比表示。
研究组由61例患者(43例男性和18例女性)组成,年龄在30至80岁之间(平均年龄=59.34岁)。男性胃癌发生率(70.5%)高于女性(29.5%)(p<0.001,效应量)。胃癌病例数随年龄增长而增加,在51-70岁年龄组患者中观察到的比例最高。然而,71岁以后的发病率显著降低 - 为8.2%(p<0.001,效应量)。在所有年龄组中,胃癌的胃窦部定位在男性和女性中均占主导(50.8%)。整个组的平均5年生存率为16.4%。我们注意到老年患者的生存率极低。在我们的研究中,我们确定了5例早期胃癌(8.2%),分类为肠型I型突出性肿瘤和56例进展期胃癌,其中女性16例(28.6%),男性40例(71.4%)。进展期胃癌患者的平均生存期为13.9个月,显著低于早期胃癌患者的平均生存值(57.2个月)。根据Borrmann分类,我们确定了5例I型癌(8.9%),20例II型癌(35.7%),22例III型癌(39.3%)和9例IV型癌(16.1%)。我们未发现I型、II型和III型肿瘤患者的生存值之间存在任何显著差异(p>0.05,无显著性差异),但弥漫性浸润性胃癌患者术后平均生存期仅为4.9个月。
胃癌的预后不容乐观,5年平均生存率为16.4%。我们注意到生存率随年龄显著下降(p = 0.024688,显著性)。进展期癌症患者的5年生存率为10.7%,显著低于早期胃癌患者80%的5年生存率(p<0.001,效应量)。溃疡浸润型癌症占主导(39.3%)。弥漫性浸润型胃癌患者在手术干预后的平均生存期仅为4.9个月。